YU9302A - Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa - Google Patents

Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa

Info

Publication number
YU9302A
YU9302A YU9302A YUP9302A YU9302A YU 9302 A YU9302 A YU 9302A YU 9302 A YU9302 A YU 9302A YU P9302 A YUP9302 A YU P9302A YU 9302 A YU9302 A YU 9302A
Authority
YU
Yugoslavia
Prior art keywords
ifn
peg
association
alpha
mycophenolate mofetil
Prior art date
Application number
YU9302A
Other languages
English (en)
Inventor
Mary Catherine Graves
Stephen Christopher Pappas
Friederike Zahm
Original Assignee
F.Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. filed Critical F.Hoffmann-La Roche Ag.
Publication of YU9302A publication Critical patent/YU9302A/sh

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Primena terapeutski efektivne količine IFN-A ili PEG1IFN-α u kombinaciji sa terapeutski efektivnom količinom farmaceutski prihvatljive soli ili proleka mikofenolatske kiseline, za proizvodnju medikamenata za terapiju pacijenata obolelih od bolesti jetre. Komponente se primenjuju tokom perioda vremena koji je dovoljan da umanji količinu HCV-RNK prisutne u perifernoj krvi naznačenog pacijenta na nivo od manje od 100 kopija(ml, 24 nedelje nakon završetka terapije.[The use of therapeutically effective amount of IFN- α or PEG-IFN-α in association with a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid for the manufacture of medicaments for treating liver diseases patients. The components are administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.
YU9302A 1999-08-13 2000-08-08 Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa YU9302A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99011595 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
YU9302A true YU9302A (sh) 2005-11-28

Family

ID=47740675

Family Applications (1)

Application Number Title Priority Date Filing Date
YU9302A YU9302A (sh) 1999-08-13 2000-08-08 Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa

Country Status (1)

Country Link
YU (1) YU9302A (sh)

Similar Documents

Publication Publication Date Title
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
SG52443A1 (en) Methods and compositions for the treatment of disease with interferon while reducing sid effects
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
GB9727131D0 (en) Therapeutic agents
JP2002544227A5 (sh)
JP2003514025A5 (sh)
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
JP2002530353A5 (sh)
RU2006101061A (ru) Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
ECSP003616A (es) Micofenolato mofetil en asociacion con peg-ifn-alfa
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
UY26292A1 (es) Micofenolato mofetilo en asociacion con peg-ifn-a ley 17164
TH54147A (th) ไมโคฟีโนเลท โมฟีทิล โนการเข้าร่วมกับ peg-ifn-อัลฟา
TH54147B (th) ไมโคฟิโนเลท โมฟิทิล โนการเข้าร่วมกับ PEG-IFN -a
RU2001128509A (ru) Способ лечения нейродегенерации
CO5150206A1 (es) Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias